Inovio Pharmaceuticals (INO) Operating Margin (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Operating Margin for 16 consecutive years, with 38336.97% as the latest value for Q1 2025.

  • Quarterly Operating Margin changed N/A to 38336.97% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 132871.32% through Dec 2025, down 8125440.0% year-over-year, with the annual reading at 132871.32% for FY2025, 8125440.0% down from the prior year.
  • Operating Margin hit 38336.97% in Q1 2025 for Inovio Pharmaceuticals, down from 17410.77% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 390.61% in Q3 2022 to a low of 44876.83% in Q4 2022.
  • Historically, Operating Margin has averaged 23434.95% across 5 years, with a median of 20553.16% in 2021.
  • Biggest YoY gain for Operating Margin was 2016255bps in 2022; the steepest drop was -3230307bps in 2022.
  • Year by year, Operating Margin stood at 12573.76% in 2021, then plummeted by -257bps to 44876.83% in 2022, then surged by 41bps to 26686.29% in 2023, then surged by 35bps to 17410.77% in 2024, then tumbled by -120bps to 38336.97% in 2025.
  • Business Quant data shows Operating Margin for INO at 38336.97% in Q1 2025, 17410.77% in Q4 2024, and 32945.87% in Q2 2024.